MX2019005202A - Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos. - Google Patents

Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos.

Info

Publication number
MX2019005202A
MX2019005202A MX2019005202A MX2019005202A MX2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A MX 2019005202 A MX2019005202 A MX 2019005202A
Authority
MX
Mexico
Prior art keywords
capsaicin
injectable
injectable formulations
stable aqueous
same
Prior art date
Application number
MX2019005202A
Other languages
English (en)
Spanish (es)
Inventor
Ostovic Drazen
Fred Musso Gary
Original Assignee
Centrexion Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrexion Therapeutics Corp filed Critical Centrexion Therapeutics Corp
Publication of MX2019005202A publication Critical patent/MX2019005202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019005202A 2016-11-02 2017-11-02 Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos. MX2019005202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416345P 2016-11-02 2016-11-02
PCT/US2017/059628 WO2018085476A1 (en) 2016-11-02 2017-11-02 Stable aqueous capsaicin injectable formulations and medical uses thereof

Publications (1)

Publication Number Publication Date
MX2019005202A true MX2019005202A (es) 2019-10-14

Family

ID=62077165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005202A MX2019005202A (es) 2016-11-02 2017-11-02 Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos.

Country Status (11)

Country Link
US (7) US11000490B2 (https=)
EP (1) EP3534961B1 (https=)
JP (1) JP7100635B2 (https=)
KR (1) KR102657458B1 (https=)
CN (1) CN110035740B (https=)
AU (1) AU2017353782B2 (https=)
CA (1) CA3041121A1 (https=)
IL (1) IL266279B2 (https=)
MX (1) MX2019005202A (https=)
NZ (1) NZ752750A (https=)
WO (1) WO2018085476A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ752750A (en) 2016-11-02 2023-05-26 Centrexion Therapeutics Corp Stable aqueous capsaicin injectable formulations and medical uses thereof
ES3018268T3 (en) 2017-07-20 2025-05-14 Centrexion Therapeutics Corp Compositions and their use for treatment of pain using capsaicin
EP3840739B1 (en) * 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
PH12021552872A1 (en) 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
CN113855626B (zh) * 2020-08-07 2023-03-24 北京泰德制药股份有限公司 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法
TR2021013305A2 (tr) * 2021-08-23 2023-03-21 Tuem Ekip Ilac Anonim Sirketi Li̇yofi̇li̇ze levosi̇mendan formülasyonlari

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5431914A (en) 1992-04-17 1995-07-11 Adekunle; Michael Method of treating an internal condition by external application of capsaicin without the need for systemic absorption
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
EP0646372B1 (de) 1993-09-30 1999-03-31 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
AU5460598A (en) 1996-11-15 1998-06-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
US6060060A (en) 1997-01-31 2000-05-09 Bmb Patent Holding Corporation Analgesic compositions from sweet peppers and methods of use thereof
ATE481970T1 (de) 1997-03-13 2010-10-15 James N Campbell Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
WO1998053825A1 (en) 1997-05-27 1998-12-03 Algos Pharmaceutical Corporation Analgesic drug composition containing a capsaicinoid and potentiator therefor
CA2442049C (en) 2001-03-22 2010-06-01 Michael J. Iadarola Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
CA2493041C (en) 2002-07-19 2011-08-16 Dominik Meyer Injectable pharmaceutical composition for treating post-operative joint pain comprising an amide local anesthetic
US20040161481A1 (en) 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
MXPA05006670A (es) * 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
ES2535045T3 (es) 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2005309586A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
EP1830836B1 (de) 2004-12-22 2010-11-24 Mestex AG Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
JP5775246B2 (ja) 2004-12-28 2015-09-09 メステックス アクチェンゲゼルシャフトＭｅｓｔｅｘ Ａｇ 関節痛を治療する薬剤を生成するためのレシニフェラトキシン（ｒｔｘ）の使用方法および前記薬剤を適用する方法
CA2594203C (en) 2004-12-28 2014-04-29 Mestex Ag Use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating articular pain and method for applying said agent
US20080160487A1 (en) 2006-12-29 2008-07-03 Fairfield Language Technologies Modularized computer-aided language learning method and system
US8222564B2 (en) 2008-02-13 2012-07-17 Tyco Healthcare Group, Lp Methods of altering surgical fiber
MX2011002688A (es) 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
CN101507818B (zh) 2008-12-15 2010-11-10 中国人民武装警察部队医学院 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
EP2688866A1 (en) 2011-03-25 2014-01-29 AbbVie Inc. Trpv1 antagonists
WO2013036961A1 (en) 2011-09-09 2013-03-14 Api Genesis Llc A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
EP2838536B1 (en) 2012-04-18 2017-08-09 Mallinckrodt LLC Immediate release pharmaceutical compositions with abuse deterrent properties
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CA2880855A1 (en) 2012-08-03 2014-02-06 Mestex Ag Resiniferatoxin solution
WO2014075084A2 (en) * 2012-11-12 2014-05-15 Api Genesis Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
MX377728B (es) 2013-02-28 2025-03-11 Pronova Biopharma Norge As Composición que comprende un compuesto lípido, un triglicerido y un tensioactivo, y métodos de uso de la misma.
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20150133561A1 (en) 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
ES2838756T3 (es) 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
WO2015160842A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Methods and formulatiions of capsaicinoids and capsinoids
EP3131541A4 (en) 2014-04-14 2018-02-14 Flex Pharma, Inc. Ion channel activators and methods of use
CA2945818C (en) 2014-04-15 2022-05-03 Vizuri Health Sciences Llc Topical compositions comprising a capsaicinoid for pain relief, manufacture and use
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
WO2015198350A1 (en) 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
WO2015198059A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
US20170239198A1 (en) 2014-08-19 2017-08-24 Mandishora Israel Muzari Capsaicinoids and uses thereof as medicaments
WO2016077749A1 (en) 2014-11-13 2016-05-19 Centrexion Therapeutics Corporation Capsaicinoids for use in treating acral lick granuloma
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CN107847451A (zh) 2015-02-02 2018-03-27 英仕柏集团有限责任公司 稳定的富马酸二烷基酯组合物
CA2987517A1 (en) 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
WO2017087803A1 (en) 2015-11-20 2017-05-26 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
US9989978B2 (en) 2016-01-21 2018-06-05 Itt Manufacturing Enterprises Llc Natural gas pressure regulator having adjustable valve seat
WO2017127628A1 (en) 2016-01-22 2017-07-27 Centrexion Therapeutics Corporation Capsaicn sequential dosing method for treatment of morton's neuroma pain
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3463576A4 (en) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA
NZ752750A (en) 2016-11-02 2023-05-26 Centrexion Therapeutics Corp Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2018217937A1 (en) 2017-05-24 2018-11-29 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia

Also Published As

Publication number Publication date
AU2017353782B2 (en) 2022-06-02
US20200046656A1 (en) 2020-02-13
US20220211649A1 (en) 2022-07-07
KR102657458B1 (ko) 2024-04-12
EP3534961B1 (en) 2026-02-11
BR112019008239A2 (pt) 2019-07-16
US11000490B2 (en) 2021-05-11
NZ752750A (en) 2023-05-26
AU2017353782A1 (en) 2019-05-16
US10772853B2 (en) 2020-09-15
CN110035740B (zh) 2023-08-04
WO2018085476A1 (en) 2018-05-11
JP7100635B2 (ja) 2022-07-13
US11344516B2 (en) 2022-05-31
KR20190101368A (ko) 2019-08-30
CN110035740A (zh) 2019-07-19
RU2019116788A (ru) 2020-12-03
US10493047B2 (en) 2019-12-03
JP2019537589A (ja) 2019-12-26
EP3534961C0 (en) 2026-02-11
US20200093765A1 (en) 2020-03-26
US20210052522A1 (en) 2021-02-25
CA3041121A1 (en) 2018-05-11
US20240423931A1 (en) 2024-12-26
EP3534961A1 (en) 2019-09-11
US11992470B2 (en) 2024-05-28
US10765649B2 (en) 2020-09-08
IL266279A (en) 2019-06-30
IL266279B2 (en) 2023-07-01
US20200093766A1 (en) 2020-03-26
RU2019116788A3 (https=) 2021-02-25
IL266279B1 (en) 2023-03-01
US20190254996A1 (en) 2019-08-22
EP3534961A4 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX2019005202A (es) Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos.
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
CU20190005A7 (es) Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2016001621A (es) Dispositivos y metodos de unidades multiples para administracion de farmacos.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
UY35988A (es) Proceso para la producción de una solución inyectable de noradrenalina de baja concentración
AR106364A1 (es) Derivados de insulina y sus usos médicos
MX394318B (es) Inhibidores pirazolicos de magl
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2017002299A1 (es) Combinaciones de dosis fija y formulaciones comprendiendo etc-1002 y ezetimiba y métodos para tratar o reducir el riesgo de enfermedades cardiovasculares
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
BR112016027435A2 (pt) formulação inovadora de meloxicam
CO2025007764A2 (es) Degradadores de irak4 y usos de los mismos
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina